$CRMD
CorMedix Inc. Stock $crmd

$crmd Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039793 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue			$7.640K
YoY Change			-91.51%
Cost Of Revenue			$1.530K
YoY Change			-97.45%
Gross Profit			$6.110K
YoY Change			-79.63%
Gross Profit Margin			79.97%
Selling, General & Admin	$7.010M	$7.610M	$4.751M
YoY Change	38.76%	60.17%	3.28%
% of Gross Profit			77755.81%
Research & Development	$4.795M	$3.408M	$2.288M
YoY Change	49.39%	48.96%	-13.35%
% of Gross Profit			37440.1%
Depreciation & Amortization	$17.43K	$16.86K	$20.25K
YoY Change	-15.26%	-16.73%	102.5%
% of Gross Profit			331.42%
Operating Expenses	$11.80M	$11.02M	$7.038M
YoY Change	42.89%	56.53%	-2.78%
Operating Profit	-$11.80M	-$11.02M	-$7.032M
YoY Change	43.25%	56.66%	-2.46%
Interest Expense	$5.851K	$8.776K	-$1.830K
YoY Change	63.21%	-579.56%	-81.7%
% of Operating Profit
Other Income/Expense, Net	$531.0K	$450.0K	-$1.833K
YoY Change	962.16%	-24647.35%
Pretax Income	-$11.27M	-$10.57M	-$7.034M
YoY Change	37.64%	50.23%	-2.57%
Income Tax
% Of Pretax Income
Net Earnings	-$11.27M	-$10.57M	-$7.034M
YoY Change	48.24%	50.23%	-2.57%
Net Earnings / Revenue			-92070.55%
Basic Earnings Per Share	-$0.25	-$0.24	-$0.18
Diluted Earnings Per Share	-$0.25	-$0.24	-$183.9K
COMMON SHARES
Basic Shares Outstanding	45.38M shares	44.50M shares	38.25M shares
Diluted Shares Outstanding	45.37M shares	44.09M shares	38.25M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$52.40M	$55.60M	$61.69M
YoY Change	-18.91%	-9.87%	-24.0%
Cash & Equivalents	$19.70M	$25.27M	$45.39M
Short-Term Investments	$32.70M	$30.33M	$16.30M
Other Short-Term Assets	$2.224M	$1.181M	$810.2K
YoY Change	202.66%	45.71%	-53.97%
Inventory			$2.610K
Prepaid Expenses	$1.255M	$2.910K
Receivables			$2.980K
Other Receivables			$0.00
Total Short-Term Assets	$54.62M	$56.78M	$62.50M
YoY Change	-16.42%	-9.15%	-24.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.597M	$1.608M	$2.328M
YoY Change	10.23%	-30.95%	111.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$102.4K	$102.4K	$102.3K
YoY Change	0.06%	0.04%	2.31%
Total Long-Term Assets	$2.408M	$2.452M	$2.430M
YoY Change	0.81%	0.9%	102.54%
TOTAL ASSETS
Total Short-Term Assets	$54.62M	$56.78M	$62.50M
Total Long-Term Assets	$2.408M	$2.452M	$2.430M
Total Assets	$57.03M	$59.23M	$64.93M
YoY Change	-15.82%	-8.78%	-22.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.901M	$1.447M	$1.740M
YoY Change	16.2%	-16.86%	16.0%
Accrued Expenses	$4.344M	$3.089M	$2.554M
YoY Change	64.02%	20.95%	64.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.387M	$4.675M	$4.294M
YoY Change	40.12%	8.85%	40.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$594.3K	$631.4K	$770.0K
YoY Change	-19.34%	-18.0%	-13.48%
Total Long-Term Liabilities	$594.3K	$631.4K	$770.0K
YoY Change	-19.34%	-18.0%	-13.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.387M	$4.675M	$4.294M
Total Long-Term Liabilities	$594.3K	$631.4K	$770.0K
Total Liabilities	$7.982M	$5.306M	$5.064M
YoY Change	32.83%	4.77%	28.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$297.2M	-$285.9M
YoY Change	14.18%
Common Stock	$45.81K	$44.50K
YoY Change	11.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$49.05M	$53.93M	$59.87M
YoY Change
Total Liabilities & Shareholders Equity	$57.03M	$59.23M	$64.93M
YoY Change	-15.82%	-8.78%	-22.94%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$11.27M	-$10.57M	-$7.034M
YoY Change	48.24%	50.23%	-2.57%
Depreciation, Depletion And Amortization	$17.43K	$16.86K	$20.25K
YoY Change	-15.26%	-16.73%	102.5%
Cash From Operating Activities	-$8.572M	-$10.39M	-$6.744M
YoY Change	56.94%	54.11%	0.81%
INVESTING ACTIVITIES
Capital Expenditures	$6.350K	$14.77K	-$4.320K
YoY Change	-164.34%	-441.81%	-56.8%
Acquisitions
YoY Change
Other Investing Activities	-$2.379M	-$14.67M	-$4.183M
YoY Change	-493.75%	250.73%	720.26%
Cash From Investing Activities	-$2.386M	-$14.69M	-$4.188M
YoY Change	-501.35%	250.72%	690.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.350M	$7.200M	3.004M
YoY Change	-36.39%	139.68%	-92.77%
NET CHANGE
Cash From Operating Activities	-8.572M	-$10.39M	-6.744M
Cash From Investing Activities	-2.386M	-$14.69M	-4.188M
Cash From Financing Activities	5.350M	$7.200M	3.004M
Net Change In Cash	-5.608M	-$17.88M	-7.928M
YoY Change	-258.26%	125.51%	-123.07%
FREE CASH FLOW
Cash From Operating Activities	-$8.572M	-$10.39M	-$6.744M
Capital Expenditures	$6.350K	$14.77K	-$4.320K
Free Cash Flow	-$8.579M	-$10.41M	-$6.740M
YoY Change	57.34%	54.43%	0.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-34673
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5894890
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Connell Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 4200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Berkeley Heights
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07922
CY2023Q1	dei	City Area Code CityAreaCode	(908)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	517-9500
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	CRMD
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45377764	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25268225	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43148323	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	126174	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	124102	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	30332493	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1051427	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	623672	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	56781229	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	59551175	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	15644062	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2910	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11016	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1607582	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1609679	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102345	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102320	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	742503	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	775085	usd
CY2023Q1	us-gaap	Assets Assets	59233659	usd
CY2022Q4	us-gaap	Assets Assets	62038259	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1446592	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2202149	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3089302	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3973941	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	138623	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134801	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4674517	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6310891	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	631388	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	667632	usd
CY2023Q1	us-gaap	Liabilities Liabilities	5305905	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6978523	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44499788	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44499788	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42815196	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42815196	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	44500	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42815	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	101232	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	82743	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	339709852	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	330294782	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-285928012	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275360786	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	53927754	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59233659	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62038259	usd
CY2022Q1	us-gaap	Revenues Revenues	7636	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1527	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	6109	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3407502	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2287587	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7609677	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4750883	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	11017179	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7038470	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11017179	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7032361	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	446384	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	13751	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	12345	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10206	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	8776	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	5378	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	449953	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1833	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10567226	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7034194	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	-16393	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	34171	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2096	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3038	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	18489	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-37209	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10548737	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7071403	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44090998	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38247059	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
CY2023Q1	crmd	Stockissuedinconnectionwith At Msaleofcommonstocknet StockissuedinconnectionwithATMsaleofcommonstocknet	7200406	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2216349	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	18489	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10567226	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	53927754	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
CY2022Q1	crmd	Stockissuedinconnectionwith At Msaleofcommonstocknet StockissuedinconnectionwithATMsaleofcommonstocknet	3004216	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1138299	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-37209	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7034194	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	59869179	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-10567226	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7034194	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2216349	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1138299	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	32582	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	30358	usd
CY2023Q1	us-gaap	Depreciation Depreciation	16863	usd
CY2022Q1	us-gaap	Depreciation Depreciation	20252	usd
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-41874	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-394	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	419578	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-141105	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-755582	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-469362	usd
CY2023Q1	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	884872	usd
CY2022Q1	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	583633	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-32422	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-29435	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10393886	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6744342	usd
CY2023Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	25422039	usd
CY2022Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	8483337	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	10750000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4300000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14766	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4324	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14686805	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4187661	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7200406	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3004216	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7200406	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3004216	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2284	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3179	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17878001	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7930966	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43374745	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53551277	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25496744	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45620311	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	8776	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	5378	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-16393	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	34171	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	25496744	usd
CY2023Q1	crmd	Market Issuance Sales Agreement MarketIssuanceSalesAgreement	24200000	usd
CY2023Q1	us-gaap	Trading Securities TradingSecurities	150000000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align: left; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Use of Estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> </p>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25268225	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43148323	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	228519	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	226422	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	514354	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	43374745	usd
CY2023Q1	crmd	Amortized Cost AmortizedCost	38343841	usd
CY2023Q1	crmd	Gross Unrealized Losses GrossUnrealizedLosses	1079	usd
CY2023Q1	crmd	Gross Unrealized Gains GrossUnrealizedGains	16870	usd
CY2023Q1	crmd	Fair Value FairValue	38359632	usd
CY2022Q4	crmd	Amortized Cost AmortizedCost	22956564	usd
CY2022Q4	crmd	Gross Unrealized Losses GrossUnrealizedLosses	4140	usd
CY2022Q4	crmd	Gross Unrealized Gains GrossUnrealizedGains	3537	usd
CY2022Q4	crmd	Fair Value FairValue	22955961	usd
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	38359632	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22955961	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1465601	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2180581	usd
CY2023Q1	crmd	Manufacturing Development Related ManufacturingDevelopmentRelated	735873	usd
CY2022	crmd	Manufacturing Development Related ManufacturingDevelopmentRelated	1214550	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	55385	usd
CY2023Q1	crmd	Total Potentially Dilutive Shares TotalPotentiallyDilutiveShares	11782480	shares
CY2022Q1	crmd	Total Potentially Dilutive Shares TotalPotentiallyDilutiveShares	9572691	shares
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	832443	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	64456	usd
CY2023Q1	crmd	Total Accured Expenses TotalAccuredExpenses	3089302	usd
CY2022	crmd	Total Accured Expenses TotalAccuredExpenses	3973941	usd
CY2020	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	30000	usd
CY2021	crmd	Cash Reimburse CashReimburse	41000	usd
CY2023Q1	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	126000	usd
CY2023Q1	us-gaap	Amount Of Impairment To Carrying Amount Of Regulatory Assets AmountOfImpairmentToCarryingAmountOfRegulatoryAssets	10000	eur
CY2023Q1	us-gaap	Amount Of Impairment To Carrying Amount Of Regulatory Assets AmountOfImpairmentToCarryingAmountOfRegulatoryAssets	50000	usd
CY2023Q1	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	126000	usd
CY2023Q1	us-gaap	Deposits Deposits	50000	usd
CY2008Q4	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
CY2008Q4	crmd	Shares Of Equity Of Common Stock SharesOfEquityOfCommonStock	7996	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	29109	shares
CY2014	crmd	Number Of Shares Released In Escrow NumberOfSharesReleasedInEscrow	7277	shares
CY2023Q1	crmd	Number Of Share Held In Escrow Of Common Stock NumberOfShareHeldInEscrowOfCommonStock	21832	shares
CY2023Q1	crmd	Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones	3000000	usd
CY2023Q1	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
CY2022Q1	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
CY2021Q3	crmd	Commission Percentage Of Gross Proceeds CommissionPercentageOfGrossProceeds	0.03	pure
CY2023Q1	crmd	Available Amount AvailableAmount	24217000	usd
CY2023Q1	crmd	Aggregate Shares AggregateShares	1684592	shares
CY2022Q1	crmd	Aggregate Shares AggregateShares	641542	shares
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	7200000	usd
CY2022Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3004000	usd
CY2023Q1	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P1Y4M13D
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q1	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
CY2023Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	8606000	usd
CY2023Q1	us-gaap	Insured Financial Obligations With Credit Deterioration Remaining Weighted Average Contract Period InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod	P1Y7M6D
CY2023Q1	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The Company entered into a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922.
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2023Q1	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
CY2023Q1	crmd	Total Operating Lease Liability TotalOperatingLeaseLiability	770000	usd
CY2023Q1	crmd	Operating Lease Liabilities Shortterm OperatingLeaseLiabilitiesShortterm	139000	usd
CY2023Q1	crmd	Operating Lease Liabilities Net Of Current Portion OperatingLeaseLiabilitiesNetOfCurrentPortion	631000	usd
CY2022	crmd	Total Operating Lease Liability TotalOperatingLeaseLiability	803000	usd
CY2022	crmd	Operating Lease Liabilities Shortterm OperatingLeaseLiabilitiesShortterm	135000	usd
CY2022Q4	crmd	Operating Lease Liabilities Net Of Current Portion OperatingLeaseLiabilitiesNetOfCurrentPortion	668000	usd
CY2023Q1	crmd	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	743000	usd
CY2022Q4	crmd	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	775000	usd
CY2023Q1	crmd	Operating Leases OperatingLeases	50000	usd
CY2022Q1	crmd	Operating Leases OperatingLeases	50000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2023Q1	crmd	Operating Leases Future Minimum Payment Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentDueInRollingYearThree	151000	usd
CY2023Q1	crmd	Operating Leases Future Minimum Payments Due In Four Year OperatingLeasesFutureMinimumPaymentsDueInFourYear	205000	usd
CY2023Q1	crmd	Operating Leases Future Minimum Payments Due In Five Year OperatingLeasesFutureMinimumPaymentsDueInFiveYear	208000	usd
CY2023Q1	crmd	Operating Leases Future Minimum Payments Due In Six Year OperatingLeasesFutureMinimumPaymentsDueInSixYear	211000	usd
CY2023Q1	crmd	Operating Leases Future Minimum Payment Due Thereafter OperatingLeasesFutureMinimumPaymentDueThereafter	169000	usd
CY2023Q1	crmd	Future Minimum Lease Payments FutureMinimumLeasePayments	944000	usd
CY2023Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	174000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	770000	usd
CY2023Q1	crmd	Atm Program Descroption ATMProgramDescroption	In April 2023 through May 5, 2023, the Company sold an aggregate of 849,476 shares of its common stock under the ATM program and realized net proceeds of approximately $3.7 million.
CY2023Q1	us-gaap	Compensating Balance Amount CompensatingBalanceAmount	20400000	usd
CY2023Q1	us-gaap	Debt And Equity Securities Gain Loss DebtAndEquitySecuritiesGainLoss	150000000	usd
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CorMedix Inc.
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables		usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001410098

Files In Submission

Name	View Source	Status
crmd-20230331_lab.xml	Edgar Link	unprocessable
0001213900-23-039793-index-headers.html	Edgar Link	pending
0001213900-23-039793-index.html	Edgar Link	pending
0001213900-23-039793.txt	Edgar Link	pending
0001213900-23-039793-xbrl.zip	Edgar Link	pending
crmd-20230331.xsd	Edgar Link	pending
f10q0323ex10-1_cormedix.htm	Edgar Link	pending
f10q0323ex31-1_cormedix.htm	Edgar Link	pending
f10q0323ex31-2_cormedix.htm	Edgar Link	pending
f10q0323ex32-1_cormedix.htm	Edgar Link	pending
f10q0323ex32-2_cormedix.htm	Edgar Link	pending
f10q0323_cormedix.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
crmd-20230331_cal.xml	Edgar Link	unprocessable
crmd-20230331_def.xml	Edgar Link	unprocessable
crmd-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_cormedix_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRMD
CorMedix Inc. Stock $crmd

2023 Q2 Form 10-Q Financial Statement

#000121390023039793 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD CorMedix Inc. Stock $crmd

2023 Q2 Form 10-Q Financial Statement

#000121390023039793 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD
CorMedix Inc. Stock $crmd